October 18, 2020
IF YOU HAVE HAD COVID SEE THIS: LIVING WITH COVID
(J. Harris: All humans on this earth should avoid becoming infected with the Covid-19 Virus now and should seek vaccination when it is available. To flauntthe dangers and possible consequences of personal infection and to ignore the possibility of transmitting the virus to others is imbecilic and, to me, unfathomable. )
FROM JOHNS HOPKINS:
1. First Patients Dosed with the First Oral COVID-19 Tablet Vaccine in Clinical Trials (Outbreak News Today) Clinical-stage biotechnology company, Vaxart, Inc., announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate.
2. Remdesivir Against COVID-19 and Other Viral Diseases (Clinical Microbiology Review) Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic. Remdesivir (GS-5734) is the first approved treatment for severe coronavirus disease 2019 (COVID-19). It is a novel nucleoside analog with a broad antiviral activity spectrum among RNA viruses, including ebolavirus (EBOV) and the respiratory pathogens Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2.
3. OBSERVED CASE-FATALITY RATE FOR SELECTED COUNTRIES
Cases and mortality by country
New confirmed cases per 1,000 people
(J. Harris: I try to limit my worries to our immediate area; here, my efforts might make some difference if I persist and do a good job translating some of the medical gibberish and try to keep politics out of medicine. The reader can follow the two above websites and get the pandemic view. I still favor following area Covid cases hospitalized and ICU beds available as my favorite stats. As of Friday, our area case rates are about the same as they were in early Sept.)
TEXAS IS IN TROUBLE, HOWEVER
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.